Avitrex

Avitrex

pemetrexed

Manufacturer:

Kimia Farma
Concise Prescribing Info
Contents
Pemetrexed
Indications/Uses
In combination w/ cisplatin for chemotherapy-naïve patients w/ unresectable malignant pleural mesothelioma. 1st-line treatment in combination w/ cisplatin in patients w/ locally advanced or metastatic non-small cell lung cancer (NSCLC) other than predominantly squamous cell histology. Monotherapy for maintenance treatment of locally advanced or metastatic NSCLC other than predominantly squamous cell histology in patients whose disease have not progressed immediately following platinum-based chemotherapy. Monotherapy as 2nd-line treatment in patients w/ locally advanced or metastatic nonsquamous NSCLC after prior chemotherapy.
Dosage/Direction for Use
In combination w/ cisplatin 500 mg/m2 IV infusion over 10 min on 1st day of each 21-day cycle (cisplatin 75 mg/m2 infused over 2 hr approx 30 min after completion of pemetrexed infusion). Monotherapy 500 mg/m2 IV infusion over 10 min on 1st day of each 21-day cycle. Premed regimen Dexamethasone 4 mg twice daily given the day prior to, on the day of & after treatment. Oral folic acid or multivit-containing folic acid 350-1,000 mcg daily at least 5 doses during the 7 days preceding 1st pemetrexed dose, continued during the full course of therapy & for 21 days after last dose of pemetrexed. IM vit B12 1,000 mcg in the wk preceding 1st pemetrexed dose & once every 3 cycles thereafter.
Contraindications
Hypersensitivity. Concomitant use w/ yellow fever vaccine. Discontinue breastfeeding during therapy.
Special Precautions
Discontinue use if grade 3 or 4 haematologic or non-haematologic toxicity or neurotoxicity is observed. Severe CV events eg, MI & cerebrovascular events; dehydration, preexisting HTN or diabetes. Not to be given to patients until absolute neutrophil count (ANC) returns to ≥1,500 cells/mm3 & platelet count returns to ≥100,000 cells/mm3. Monitor for myelosuppression during therapy; complete blood & platelet counts prior to therapy. Adequate antiemetic treatment & appropriate hydration prior to &/or after treatment. Not recommended in concomitant use w/ live attenuated vaccines. Concomitant use of other radiosensitizing agents. May affect ability to drive & use machines. Avoid NSAIDs for 2 days prior to, on the day of & 2 days following pemetrexed administration in patients w/ mild to moderate renal impairment (CrCl 45-79 mL/min). Not recommended in patients w/ CrCl <45 mL/min. Males should not father a child during & up to 6 mth treatment. Women of childbearing potential should use effective contraception during treatment. Not to be used during pregnancy. Discontinue breastfeeding during therapy. Not recommended to be used in childn <18 yr.
Adverse Reactions
Decreased neutrophils/granulocytes, leukocytes, Hb, platelets; sensory neuropathy; diarrhea, vomiting, stomatitis/pharyngitis, nausea, anorexia, constipation; rash, alopecia; elevated creatinine, decreased CrCl; fatigue. Dehydration; taste disturbance; conjunctivitis; dyspepsia.
Drug Interactions
Delayed clearance w/ nephrotoxic drugs (eg, aminoglycosides, loop diuretics, platinum comp & cyclosporine), probenecid, penicillin. Decreased elimination & increased occurrence of adverse events w/ high-dose NSAIDs (NSAIDs eg, as ibuprofen >1,600 mg/day) & aspirin (≥1,300 mg daily). Monitor increased INR frequency w/ oral anticoagulants. Risk of fatal generalized vaccine disease w/ yellow fever vaccine. Increased risk of systemic, possibly fatal disease w/ live attenuated vaccines.
ATC Classification
L01BA04 - pemetrexed ; Belongs to the class of antimetabolites, folic acid analogues. Used in the treatment of cancer.
Presentation/Packing
Form
Avitrex lyo powd for injection 500 mg
Packing/Price
(lyo) 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in